Efficacy of postoperative intraperitoneal hyperthermic perfusion chemotherapy with oxaliplatin+5-Fluorouracil in the treatment of gastric cancer patients with peritoneal carcinomatosis

被引:0
|
作者
Yan, Kangpeng [1 ]
Wu, Kun [1 ]
Yan, Lan [2 ]
Liang, Lei [3 ]
Yuan, Yujun [4 ]
机构
[1] Jiangxi Canc Hosp, Abdominal Surg Oncol Ward 1, 159 Beijing East Rd, Nanchang 330029, Jiangxi, Peoples R China
[2] Jiangxi Canc Hosp, Dept Radiol, Nanchang, Jiangxi, Peoples R China
[3] Tangshan Peoples Hosp, Dept Gastroenter Surg, Tangshan, Peoples R China
[4] Quannan Peoples Hosp Jiangxi Prov, Dept Gen Surg, Ganzhou, Peoples R China
来源
JOURNAL OF BUON | 2019年 / 24卷 / 04期
关键词
gastric cancer; peritoneal carcinomatosis; oxaliplatin; 5-fluorouracil; intraperitoneal hyperthermic perfusion chemotherapy; CYTOREDUCTIVE SURGERY; SURVIVAL; TUMORS; HIPEC;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To explore the effect of palliative laparoscopic resection of gastric cancer combined with intraperitoneal hyperthermic perfusion chemotherapy (IHPC) with oxaliplatin + 5-fluorouracil (5-FU) on gastric cancer patients with peritoneal carcinomatosis (PC). Methods: 90 patients definitely diagnosed with gastric adenocarcinoma and PC and admitted to our hospital from March 2013 to March 2016 were collected and divided into IHPC group (n=45) and control group (n=45). In IHPC group, IHPC with oxaliplatin + 5-FU was carried out for the first time on the first day after operation, and then it was conducted once every other day for a total of 4 times. The clinical efficacy, quality of life, adverse reactions, postoperative tumor recurrence and survival of the patients were observed and recorded. Results: The total effective rates in IHPC group and control group were 62.2% (28/45) and 55.6% (25/45), respectively (p>0.05). In both groups, the curative effect was the best in moderately differentiated adenocarcinoma and worst in signet ring cell carcinoma. Besides, the effective rates of Karnofsky performance status (KPS) in the two groups after operation were 82.2% (37/45) and 75.6% (34/45), respectively (p=0.606). However, the renal function indexes, serum creatinine (sCr) and blood urea nitrogen (BUN) in the two groups of patients after operation were increased, and those in the IHPC group were higher than those in the control group (p=0.016, p=0.010). Moreover, follow-up results of patients' survival revealed that the OS and PFS in the IHPC group were significantly higher than those in the control group (p=0.041, p=0.045). Conclusions: Palliative laparoscopic resection of gastric cancer combined with IHPC with oxaliplatin + 5-FU has a definite therapeutic effect on gastric cancer with PC, which can achieve a better short-term clinical therapeutic effect and better postoperative quality of life
引用
收藏
页码:1587 / 1594
页数:8
相关论文
共 50 条
  • [11] Clinical Efficacy of Combination Intravenous and Intraperitoneal Chemotherapy in the Treatment of Gastric Cancer with Peritoneal Carcinomatosis
    Zhang, Suyun
    Feng, Rui
    Pan, Zhangchi
    Lin, Mengxin
    Huang, Xiaobing
    Jiang, Tao
    Xu, Qian
    Chen, Qiang
    Yang, Sheng
    CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2018, 19 (12) : 946 - 952
  • [12] Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for the treatment of endometrial cancer with peritoneal carcinomatosis
    Jerome, Delotte
    Mariangela, Desantis
    Melanie, Frigenza
    Delphine, Quaranta
    Andre, Bongain
    Daniel, Benchimol
    Marc, Bereder Jean
    EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2014, 172 : 111 - 114
  • [13] Peritoneal carcinomatosis in patients with gastric cancer, and the role for surgical resection, cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy
    Kim, Ki Won
    Chow, Oliver
    Parikh, Kunal
    Blank, Sima
    Jibara, Ghalib
    Kadri, Hena
    Labow, Daniel M.
    Hiotis, Spiros P.
    AMERICAN JOURNAL OF SURGERY, 2014, 207 (01): : 78 - 83
  • [14] Safety and Efficacy of Hyperthermic Intraperitoneal Chemoperfusion with High-Dose Oxaliplatin in Patients with Peritoneal Carcinomatosis
    Wim P. Ceelen
    Marc Peeters
    Philippe Houtmeyers
    Christophe Breusegem
    Filip De Somer
    Piet Pattyn
    Annals of Surgical Oncology, 2008, 15 : 535 - 541
  • [15] Treatment of peritoneal carcinomatosis with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
    Roviello, F.
    Caruso, S.
    Marrelli, D.
    Pedrazzani, C.
    Neri, A.
    De Stefano, A.
    Pinto, E.
    GIORNALE DI CHIRURGIA, 2011, 32 (04): : 211 - 233
  • [16] Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy in the treatment of peritoneal carcinomatosis
    Gammon, David C.
    Dutton, Traci
    Piperdi, Bilal
    Zybert, Jason
    Wolfe, Steven H.
    Nguyen, Erin
    Sbat, Dalia
    Pillarisetty, Venu G.
    Sullivan, Mary
    Whalen, Giles F.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2009, 66 (13) : 1186 - 1190
  • [17] Safety and efficacy of hyperthermic intraperitoneal chemoperfusion with high-dose oxaliplatin in patients with peritoneal carcinomatosis
    Ceelen, Wim P.
    Peeters, Marc
    Houtmeyers, Philippe
    Breusegem, Christophe
    De Somer, Filip
    Pattyn, Piet
    ANNALS OF SURGICAL ONCOLOGY, 2008, 15 (02) : 535 - 541
  • [18] INTRAPERITONEAL HYPERTHERMIC CHEMOTHERAPY (IPHC), A PROMISING TREATMENT OF PERITONEAL CARCINOMATOSIS
    DETROZ, B
    ELIAS, D
    DAMIA, E
    DEBAENE, B
    ROUGIER, P
    LASSER, P
    BULLETIN DU CANCER, 1994, 81 (03) : 182 - 193
  • [19] Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with colon cancer and peritoneal carcinomatosis
    Glockzin, G.
    Ghali, N.
    Schlitt, H. J.
    Piso, P.
    ANNALS OF SURGICAL ONCOLOGY, 2008, 15 : 93 - 93
  • [20] Long term survival analysis after hyperthermic intraperitoneal chemotherapy with oxaliplatin as a treatment for appendiceal peritoneal carcinomatosis
    Masckauchan, Daiana
    Trabulsi, Nora
    Dube, Pierre
    Aube-Lecompte, Marie-Eve
    Cloutier, Alexis-Simon
    Mitchell, Andrew
    Sideris, Lucas
    SURGICAL ONCOLOGY-OXFORD, 2019, 28 : 69 - 75